ReviewJournal of neuromuscular diseases
New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.
Review in Journal of neuromuscular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.Nature medicine · 2023Pooled it
- Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options.Clinical rheumatology · 2022Pooled it
- Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).Journal of neurology · 2026Trial
- Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Trial
- Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.Neurology · 2023Trial
- Monocyte-macrophage SAMHD1 alleviates EAMG by modulating the cGAS-STING pathway.Journal of neuroinflammation · 2026Article
- Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.Therapeutic advances in neurological disorders · 2026Article
- What Patients Don't Say and Physicians Don't Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives.Neurology and therapy · 2025Article
- A Case of Pediatric Myasthenia Revealed by Marked Eyelid Ptosis After Using Cyclopentolate Eye Drops.Cureus · 2025Article
- Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study.Therapeutic advances in neurological disorders · 2025Article
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.Advances in therapy · 2024Article
- Treating myasthenia gravis beyond the eye clinic.Eye (London, England) · 2024Review
- Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod.Frontiers in immunology · 2024Article
- Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients.Frontiers in neurology · 2024Article
- Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.European journal of neurology · 2024Article
- Structure, function and drug discovery of GPCR signaling.Molecular biomedicine · 2023Review
- Review
- Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.Frontiers in neurology · 2023Article
- Novel Immunotherapies for Myasthenia Gravis.ImmunoTargets and therapy · 2023Review
- Single-cell transcriptomics and network pharmacology reveal therapeutic targets of Jianpi Yiqi Bugan Yishen decoction in immune cell subsets of children with myasthenia gravis.Translational pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired Myasthenia Gravis (MG) is a neuromuscular disease caused by autoantibodies against components of the neuromuscular junction. It is a prototype organ-specific autoimmune disease with well-defined antigenic targets mainly the nicotinic acetylcholine receptor (AChR). Patients suffer from fluctuating, fatigable muscle weakness that worsens with activity and improves with rest.Various therapeutic strategies have been used over the years to alleviate MG symptoms. These strategies aim at improving the transmission of the nerve impulse to muscle or at lowering the immune system with steroids or immunosuppressant drugs. Nevertheless, MG remains a chronic disease and symptoms tend to persist in many patients, some being or becoming refractory over time. In this review, based on recent experimental data on MG or based on results from clinical trials for other autoimmune diseases, we explore new potential therapeutic approaches for MG patients, going from non-specific approaches with the use of stem cells with their anti-inflammatory and immunosuppressive properties to targeted therapies using monoclonal antibodies specific for cell-surface antigens or circulating molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.